UNITED THERAPEUTICS Corp
UTHR · XNASCIK 1082554fmd_077A3WEM1Q3N29BM05DYGDVGDMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 71 periods
Latest annual · FY2025
Millions- Total revenues
- 3,183
- Gross profit
- 2,798
- Operating income
- 1,493
- Net income
- 1,335
- Free cash flow
- 1,041
Latest quarter · Q3 FY2026
Millions- Total revenues
- 833
- Gross profit
- 733
- Operating income
- 308
- Net income
- 259
- Free cash flow
- 126
Daily close · UTHRIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions595.49 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +18.0%
- Revenue, 5 yearsFY2020 to FY2025
- +16.5%
- Net income, 5 yearsFY2020 to FY2025
- n/m
UNITED THERAPEUTICS Corp (UTHR) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $3.2 billion | $2.9 billion | +10.6% | 10-K 2026-02-25 · proof |
| Gross profit | $2.8 billion | $2.6 billion | +9% | 10-K 2026-02-25 · proof |
| Operating income | $1.5 billion | $1.4 billion | +8.4% | 10-K 2026-02-25 · proof |
| Net income | $1.3 billion | $1.2 billion | +11.7% | 10-K 2026-02-25 · proof |
| Cash from operating activities | $1.6 billion | $1.3 billion | +17.6% | 10-K 2026-02-25 · proof |
| Free cash flow | $1 billion | $1.1 billion | -3.7% | 10-K 2026-02-25 · proof |
| Total assets | $7.9 billion | $7.4 billion | +7% | 10-K 2026-02-25 · proof |
| Total liabilities | $783.8 million | $920 million | -14.8% | 10-K 2026-02-25 · proof |
| Cash and cash equivalents | $1.6 billion | $1.7 billion | -8.3% | 10-K 2026-02-25 · proof |
- What was UNITED THERAPEUTICS Corp (UTHR)'s revenue in fiscal 2025?
- UNITED THERAPEUTICS Corp (UTHR) reported revenue of $3.2 billion for fiscal 2025 (the year ended Dec 31, 2025), against $2.9 billion the year before (+10.6%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was UNITED THERAPEUTICS Corp (UTHR)'s gross profit in fiscal 2025?
- UNITED THERAPEUTICS Corp (UTHR) reported gross profit of $2.8 billion for fiscal 2025 (the year ended Dec 31, 2025), against $2.6 billion the year before (+9%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was UNITED THERAPEUTICS Corp (UTHR)'s operating income in fiscal 2025?
- UNITED THERAPEUTICS Corp (UTHR) reported operating income of $1.5 billion for fiscal 2025 (the year ended Dec 31, 2025), against $1.4 billion the year before (+8.4%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was UNITED THERAPEUTICS Corp (UTHR)'s net income in fiscal 2025?
- UNITED THERAPEUTICS Corp (UTHR) reported net income of $1.3 billion for fiscal 2025 (the year ended Dec 31, 2025), against $1.2 billion the year before (+11.7%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was UNITED THERAPEUTICS Corp (UTHR)'s cash from operating activities in fiscal 2025?
- UNITED THERAPEUTICS Corp (UTHR) reported cash from operating activities of $1.6 billion for fiscal 2025 (the year ended Dec 31, 2025), against $1.3 billion the year before (+17.6%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was UNITED THERAPEUTICS Corp (UTHR)'s free cash flow in fiscal 2025?
- UNITED THERAPEUTICS Corp (UTHR) reported free cash flow of $1 billion for fiscal 2025 (the year ended Dec 31, 2025), against $1.1 billion the year before (-3.7%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are UNITED THERAPEUTICS Corp (UTHR)'s total assets?
- As of Dec 31, 2025, UNITED THERAPEUTICS Corp (UTHR) reported total assets of $7.9 billion, against $7.4 billion a year earlier (+7%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are UNITED THERAPEUTICS Corp (UTHR)'s total liabilities?
- As of Dec 31, 2025, UNITED THERAPEUTICS Corp (UTHR) reported total liabilities of $783.8 million, against $920 million a year earlier (-14.8%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are UNITED THERAPEUTICS Corp (UTHR)'s cash and cash equivalents?
- As of Dec 31, 2025, UNITED THERAPEUTICS Corp (UTHR) reported cash and cash equivalents of $1.6 billion, against $1.7 billion a year earlier (-8.3%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:UTHR&period_type=annual&limit=5"Information only, not investment advice.